Literature DB >> 9265812

Similarities and differences in assessing nausea on a verbal category scale and a visual analogue scale.

S Börjeson1, T J Hursti, C Peterson, M Fredikson, C J Fürst, E Avall-Lundqvist, G Steineck.   

Abstract

The use of verbal category scales in assessing patient symptoms is evolving, but the extent to which reliability and precision are lost in using them as opposed to a visual analogue scale (VAS) remains uncertain. The present study analyzed the concordance between a four-point verbal category scale and a VAS in assessing nausea intensity in patients undergoing chemotherapy. The analysis of a total of 348 simultaneous ratings by 104 women over four cycles revealed good concordance between the scales. The means of the VAS ratings (range 0-100 mm) corresponding to the four verbal categories divided the scale in four almost equally large parts (no nausea = 0.7, mild = 24.8, moderate = 48.3, severe = 75.1). However, the VAS ranges were wide. On an individual level a one-step change in the verbal category was associated with an average change of 20 mm on the VAS. The choice of scale to use should be based on the need in the particular situation. When measuring intensity of nausea in patients, the VAS is a reasonable choice due to its possibly greater ability to detect changes over time. On the group level, findings on a four-point category scale and a VAS on the average seem similar.

Entities:  

Mesh:

Year:  1997        PMID: 9265812     DOI: 10.1097/00002820-199708000-00005

Source DB:  PubMed          Journal:  Cancer Nurs        ISSN: 0162-220X            Impact factor:   2.592


  20 in total

1.  Auricular acupuncture, education, and smoking cessation: a randomized, sham-controlled trial.

Authors:  Ian D Bier; Jeffrey Wilson; Pat Studt; Mary Shakleton
Journal:  Am J Public Health       Date:  2002-10       Impact factor: 9.308

2.  Cost-utility analysis of aprepitant for patients who truly need it in Japan.

Authors:  Ikuto Tsukiyama; Masahiko Ando; Sumiyo Tsukiyama; Masayuki Takeuchi; Masayuki Ejiri; Yusuke Kurose; Hiroko Saito; Ichiro Arakawa; Tadao Inoue; Etsuro Yamaguchi; Akihito Kubo
Journal:  Support Care Cancer       Date:  2019-02-01       Impact factor: 3.603

3.  Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Authors:  Rudolph M Navari; Rui Qin; Kathryn J Ruddy; Heshan Liu; Steven F Powell; Madhuri Bajaj; Leah Dietrich; David Biggs; Jacqueline M Lafky; Charles L Loprinzi
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

4.  Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes.

Authors:  Chi-Ting Liau; Nei-Min Chu; Hsueh-Erh Liu; Robert Deuson; Jade Lien; Jen-Shi Chen
Journal:  Support Care Cancer       Date:  2005-03-16       Impact factor: 3.603

5.  Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients' quality of life.

Authors:  P Fernández-Ortega; M T Caloto; E Chirveches; R Marquilles; J San Francisco; A Quesada; C Suárez; I Zorrilla; J Gómez; P Zabaleta; G Nocea; A Llombart-Cussac
Journal:  Support Care Cancer       Date:  2012-03-31       Impact factor: 3.603

6.  Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer.

Authors:  Charlotte C Sun; Diane C Bodurka; Candice B Weaver; Rafia Rasu; Judith K Wolf; Michael W Bevers; Judith A Smith; J Taylor Wharton; Edward B Rubenstein
Journal:  Support Care Cancer       Date:  2004-11-09       Impact factor: 3.603

7.  Palonosetron exhibits higher total control rate compared to first-generation serotonin antagonists and improves appetite in delayed-phase chemotherapy-induced nausea and vomiting.

Authors:  Hiroki Ueda; Chigusa Shimono; Tomoyasu Nishimura; Megumi Shimamoto; Hiroki Yamaue
Journal:  Mol Clin Oncol       Date:  2014-02-20

8.  Chemotherapy-induced nausea and vomiting in routine practice: a European perspective.

Authors:  Agnes Glaus; Cornelia Knipping; Rudolf Morant; Christel Böhme; Burkhard Lebert; Frank Beldermann; Bernhard Glawogger; Paz Fernandez Ortega; André Hüsler; Robert Deuson
Journal:  Support Care Cancer       Date:  2004-10       Impact factor: 3.603

9.  Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium.

Authors:  Lieven Annemans; Daniëlle Strens; Erica Lox; Christine Petit; Hughes Malonne
Journal:  Support Care Cancer       Date:  2007-10-27       Impact factor: 3.603

10.  One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient.

Authors:  Anna Enblom; Beata Bergius Axelsson; Gunnar Steineck; Mats Hammar; Sussanne Börjeson
Journal:  Support Care Cancer       Date:  2008-06-05       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.